The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Evaluating the Efficiency of Targeted Designs for Randomized Clinical Trials
Open accessAbstract
Purpose: Genomic technologies make it increasingly possible to identify patients most likely to benefit from a molecularly targeted drug. This creates the opportunity to conduct targeted clinical trials with eligibility restricted to patients predicted to be responsive to the drug. Experimental Design: We evaluated the relative efficiency of a targeted clinical trial design to an untargeted design for a randomized clinical trial comparing a new treatment to a control. Efficiency was evaluated with regard to number of patients required for randomization and number required for screening. Results: The effectiveness of this design, relative to the more traditional design with broader eligibility, depends on multiple factors, including the proportion of responsive patients, the accuracy of the assay for predicting responsiveness, and the degree to which the mechanism of action of the drug is understood. Explicit formulas were derived for computing the relative efficiency of targeted versus untargeted designs. Conclusions: Targeted clinical trials can dramatically reduce the number of patients required for study in cases where the mechanism of action of the drug is understood and an accurate assay for responsiveness is available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
Self-citationShipp, M. A., Ross, K. N., Tamayo, P., Weng, A. P., Kutok, J. L., Aguiar, R. C. T., Gaasenbeek, M., Angelo, M., Reich, M., Pinkus, G. S., et al. (2002) · Nature Medicine · doi:10.1038/nm0102-68 · Cited by 2,428
Giaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G., Rosell, R., Miller, V., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,716
Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V., Manegold, C., Scagliotti, G., Rosell, R., Oliff, I., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,707
Casagrande, J. T., Pike, M. C., & Smith, P. G. (1978) · Biometrics · doi:10.2307/2530613 · Cited by 431
Evans, W. K. (. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.08.002 · Cited by 405
Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment
Grunwald, V., & Hidalgo, M. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.12.851 · Cited by 383
Cited by
Mandrekar, S. J., & Sargent, D. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3701 · Cited by 404
Roadmap for Developing and Validating Therapeutically Relevant Genomic Classifiers
Simon, R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.8712 · Cited by 382
Self-citationRandomized Clinical Trials With Biomarkers: Design Issues
Freidlin, B., McShane, L. M., & Korn, E. L. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp477 · Cited by 369
Freidlin, B., & Simon, R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0605 · Cited by 349
Self-citationKirkwood, J. M., Bastholt, L., Robert, C., Sosman, J., Larkin, J., Hersey, P., Middleton, M., Cantarini, M., Zazulina, V., Kemsley, K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1491 · Cited by 278
Metadata
- Authors
- Simon, R., & Maitournam, A.
- Venue
- Clinical Cancer Research
- Published
- 2004-10-15
- Volume
- 10
- Issue
- 20
- Pages
- 6759-6763
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2161630562
- Cited by
- 325
- References
- 14
- FWCI
- 15.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluating the Efficiency of Targeted Designs for Randomized Clinical Trials. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-04-0496
- The paper
- Simon, R., & Maitournam, A. (2004). Evaluating the Efficiency of Targeted Designs for Randomized Clinical Trials. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-04-0496
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.